Detail of "150399-23-8"

CAS Number:
150399-23-8
Name:
Pemetrexed disodium
Molecular Structure:
Formula:
C₂₀H₁₉N₅Na₂O₆
Molecular Weight:
471.37
Synonyms:
Tifolar;L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt;Disodium (2S)-2-({4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}amino)pentanedioate;
Appearance:
crystalline solid
Hazard Symbols:
T,Xi
Risk Codes:
36/38-60-61-68
Safety:
36/37/39-53 Details

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Page：1/2

Supplier Location
Supplier Location
- China (Mainland)(52)
- India(4)
- United States(3)
- Hong Kong(1)
Business Type
Business Type
- Lab/Research institutions(8)
- Manufacturers(5)
- Other(1)
- Trading Company(42)
Certificates
Certificates
- Production License(3)
- ISO(2)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Total:61 Page 1 of 2 1 2 Next>>

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer: All Rights Reserved. A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer. Dittrich, Christian; Petruzelka, Lubos; Vodvarka, Pavel; Gneist, Margit; Janku, Filip; Kysela, Tamara; Melemed, Allen; Latz, Jane; Simms, Lorinda; Krejcy, Kurt (Ludwig Boltzmann Institute for Applied Cancer Research and Applied Cancer Research-Institution for Translational Research, Kaiser Franz Josef Spital, Vienna, Austria). Clinical Cancer Research, 12(23), 7071-7078 (English) 2006 American Association for Cancer Research. CODEN: CCREF4. ISSN: 1078-0432. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Purpose: Det. the max. tolerated dose (MTD) of pemetrexed and cyclophosphamide combination therapy for patients with locally advanced or metastatic breast cancer. Exptl. Design: Patients with locally advanced or metastatic breast cancer and WHO performance status 0 to 2 were eligible. Pemetrexed (range, 400-2,400 mg/m2) was administered on day 1 of a 21-day schedule followed by cyclophosphamide (range, 400-800 mg/m2). Folic acid and vitamin B12 supplementation began 1 to 2 wk before the first pemetrexed dose. Results: Fifty-seven pretreated patients were enrolled and received 342 cycles (median, 4 cycles; range, 1-26) through 14 dose levels. The MTD of pemetrexed was 2,400 mg/m2 (combined with cyclophosphamide, 600 mg/m2) with dose-limiting toxicities of grade 4 neutropenia with grade 4 infection and grade 3 diarrhea. Other grade 3 or 4 toxicities included (febrile) neutropenia, thrombocytopenia, anemia, elevated alanine aminotransferase/aspartate aminotransferase, and diarrhea. Pharmacokinetic anal. indicated that pemetrexed clearance and central vol. of distribution were 40% lower than single-agent ref.There are some commonly used reagents with their cas registry numbers 150399-23-8 and 50-18-0 in this article. data, yielding a 68% increase in total systemic exposure and a 56% increase in maximal plasma concn. Among the 50 patients evaluable for efficacy, 13 (26%) patients had a partial response and 17 (34%) patients had stable disease. Conclusions: Pemetrexed was generally well tolerated. The obsd. toxicities were consistent with the known toxicity profiles of pemetrexed and cyclophosphamide. Considering the MTD and the toxicity and efficacy results in this and prior studies, a low (600 mg/m2) and a high (1,800 mg/m2) dose of pemetrexed with cyclophosphamide (600 mg/m2) will be evaluated in the consecutive prospective randomized phase II study. .

Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in b-catenin-deficient human mesothelioma cells: Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in b-catenin-deficient human mesothelioma cells. He, Biao; Lee, Amie Y.; Dadfarmay, Sina; You, Liang; Xu, Zhidong; Reguart, Noemi; Mazieres, Julien; Mikami, Iwao; McCormick, Frank; Jablons, David M. (Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA, USA). Cancer Research, 65(3), 743-748 (English) 2005 American Association for Cancer Research. CODEN: CNREA8.Some commonly used reagents like 371761-91-0 and 150399-23-8 are used in this experiment. ISSN: 0008-5472. DOCUMENT TYPE: Journal CA Section: 14 (Mammalian Pathological Biochemistry) Section cross-reference(s): 3 The secreted frizzled-related proteins (SFRPs) function as neg. regulators of Wnt signaling and have important implications in tumorigenesis. Frequent promoter hypermethylation of SFRPs has been identified in human cancer. Restoration of SFRP function attenuates Wnt signaling and induces apoptosis in a variety of cancer types. Wnt signaling is known to inhibit apoptosis through activation of b-catenin/Tcf-mediated transcription. Recently, the authors identified aberrant Wnt activation as a result of Dishevelled overexpression in malignant mesothelioma. Here, the authors report that silencing of SFRP4 is correlated with promoter hypermethylation in b-catenin-deficient mesothelioma cell lines. Reexpression of SFRP4 in these b-catenin-deficient mesothelioma cell lines blocks Wnt signaling, induces apoptosis, and suppresses growth. Conversely, knocking down SFRP4 by small interfering RNA in cell lines expressing both SFRP4 and b-catenin stimulates Wnt signaling, promotes cell growth, and inhibits chemodrug-induced apoptosis. The authors' results suggest that methylation silencing of SFRP4 may play an important role in aberrant Wnt activation in mesothelioma even in the absence of b-catenin. The authors' data also suggest that b-catenin-independent noncanonical pathway(s) may be involved in the apoptotic inhibition caused by activation of Wnt signaling. .

Detail of "150399-23-8"

Pemetrexed disodium

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

CAS No.150399-23-8 Pemetrexed disodium

Reference